review article | Q7318358 |
scholarly article | Q13442814 |
P2093 | author name string | Ji-Guang Wang | |
Eduardo Pimenta | |||
Frank Chwallek | |||
P2860 | cites work | Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients | Q27023161 |
Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack | Q28190600 | ||
Guidelines for the Early Management of Adults With Ischemic Stroke | Q28297859 | ||
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients | Q29619542 | ||
Standards of medical care in diabetes--2013 | Q29620309 | ||
Telmisartan, ramipril, or both in patients at high risk for vascular events | Q33156143 | ||
Ambulatory blood pressure as a predictor of target organ disease and outcome in the hypertensive patient | Q33734535 | ||
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A | Q33989952 | ||
Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials | Q34276433 | ||
Perindopril: an updated review of its use in hypertension | Q34277843 | ||
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial | Q34327991 | ||
Telmisartan: a review of its use in hypertension | Q34370482 | ||
Perindopril: the evidence of its therapeutic impact in hypertension. | Q34450527 | ||
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study | Q34494252 | ||
The role of the renin-angiotensin system in the development of cardiovascular disease | Q34522515 | ||
Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). | Q34539439 | ||
Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis | Q34558240 | ||
The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition | Q34584353 | ||
Telmisartan to prevent recurrent stroke and cardiovascular events | Q34596294 | ||
Treatment of hypertension in patients 80 years of age or older | Q34766135 | ||
Adherence to antihypertensive medications and health outcomes among newly treated hypertensive patients | Q35205415 | ||
Angiotensin-converting enzyme inhibitors versus AT1 receptor antagonist in cardiovascular and renal protection: the case for AT1 receptor antagonist | Q35611136 | ||
Incidence of adverse events with telmisartan compared with ACE inhibitors: evidence from a pooled analysis of clinical trials | Q35684200 | ||
A review of Perindopril in the reduction of cardiovascular events | Q36012986 | ||
The cardiovascular continuum and renin-angiotensin-aldosterone system blockade | Q36094182 | ||
Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study | Q36143544 | ||
Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials | Q36247551 | ||
Perindopril. A review of its pharmacological properties and therapeutic use in cardiovascular disorders | Q36691446 | ||
Renin-angiotensin system and cardiovascular risk | Q36784673 | ||
Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort study | Q37141972 | ||
Telmisartan versus angiotension-converting enzyme inhibitors in the treatment of hypertension: a meta-analysis of randomized controlled trials | Q37318758 | ||
Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials | Q37869264 | ||
Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin-angiotensin system blockers | Q38005041 | ||
Level of systolic blood pressure within the normal range and risk of recurrent stroke | Q38481061 | ||
Immediate and late benefits of treating very elderly people with hypertension: results from active treatment extension to Hypertension in the Very Elderly randomised controlled trial | Q38899330 | ||
Discordance between meta-analyses and large-scale randomized, controlled trials. Examples from the management of acute myocardial infarction | Q40374325 | ||
Meta-analysis: statistical alchemy for the 21st century | Q40590999 | ||
Cough and inhibition of the renin-angiotensin system. | Q40818011 | ||
Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial | Q42542786 | ||
Telmisartan plus HCTZ vs. amlodipine plus HCTZ in older patients with systolic hypertension: results from a large ambulatory blood pressure monitoring study. | Q42685521 | ||
??? | Q28267062 | ||
Perindopril, amlodipine and telmisartan improve arterial stiffness in patients with hypertension | Q43171086 | ||
Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients | Q43425314 | ||
Blood-pressure lowering for the secondary prevention of stroke | Q43758874 | ||
Cardiovascular protection and blood pressure reduction: a meta-analysis | Q43782892 | ||
In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist | Q44106391 | ||
Comparison of trough effect of telmisartan vs perindopril using self blood pressure measurement: EVERESTE study | Q44274796 | ||
Different effect of antihypertensive drugs on conduit artery endothelial function | Q44420485 | ||
Effects of ARB or ACE-inhibitor administration on plasma levels of aldosterone and adiponectin in hypertension | Q44680425 | ||
Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial | Q44945181 | ||
The efficacy of telmisartan compared with perindopril in patients with mild-to-moderate hypertension. | Q45200033 | ||
Clinical evidence from ONTARGET: the value of an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor. | Q45934964 | ||
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients | Q46217490 | ||
Telmisartan to prevent recurrent stroke: the PRoFESS study: was the baby thrown out with the bathwater? | Q46225191 | ||
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. | Q46426098 | ||
Impact of the therapy by renin-angiotensin system targeting antihypertensive agents perindopril versus telmisartan on prothrombotic state in essential hypertension | Q46729379 | ||
A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure | Q46795772 | ||
Telmisartan: a review of its use in the management of hypertension | Q46883816 | ||
Effects of antihypertensive treatment after acute stroke in the Continue or Stop Post-Stroke Antihypertensives Collaborative Study (COSSACS): a prospective, randomised, open, blinded-endpoint trial. | Q51761511 | ||
Single-pill combination of telmisartan/amlodipine in patients with severe hypertension: results from the TEAMSTA severe HTN study. | Q53382421 | ||
2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). | Q55057254 | ||
Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document | Q56970676 | ||
Superiority of Ambulatory Over Clinic Blood Pressure Measurement in Predicting Mortality | Q57085545 | ||
Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial | Q57274347 | ||
ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT | Q57312509 | ||
The perindopril in elderly people with chronic heart failure (PEP-CHF) study | Q61716699 | ||
Case-control study, meta-analysis, and bouillabaisse: putting the calcium antagonist scare into context | Q71555904 | ||
Prevention of stroke and myocardial infarction by amlodipine and Angiotensin receptor blockers: a quantitative overview | Q80336135 | ||
Vascular outcome in type 2 diabetes: an ADVANCE? | Q80979913 | ||
Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis | Q81448549 | ||
Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study | Q82984878 | ||
P275 | copyright license | Creative Commons Attribution-NonCommercial | Q6936496 |
P407 | language of work or name | English | Q1860 |
P921 | main subject | arterial hypertension | Q41861 |
hydrocarbon | Q43648 | ||
carboxylic acid | Q134856 | ||
blood pressure | Q82642 | ||
antihypertensive drug | Q575890 | ||
mechanism of action | Q3271540 | ||
P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
P304 | page(s) | 189-200 | |
P577 | publication date | 2014-04-05 | |
P1433 | published in | Vascular Health and Risk Management | Q7916443 |
P1476 | title | Comparative review of the blood pressure-lowering and cardiovascular benefits of telmisartan and perindopril | |
P478 | volume | 10 |
Q42412744 | Effect of antihypertensive agents - captopril and nifedipine - on the functional properties of rat heart mitochondria |
Q48353216 | Efficacy and tolerability of initial high vs low doses of S-(-)-amlodipine in hypertension |
Q54964860 | L-Arginine and B vitamins improve endothelial function in subjects with mild to moderate blood pressure elevation. |
Q42864618 | Perindopril for improving cardiovascular events |
Q58704538 | Therapeutic effects of injection combined with telmisartan in patients with diabetic nephropathy by influencing collagen IV and fibronectin: A case-control study |
Search more.